Pairwise difference (95% CrI) for letters gained from baseline (random treatment effects model)
| Comparator | Sham | Ranibizumab 0.5 mg PRN | Aflibercept 2q4 | Laser photocoagulation | Dexamethasone 0.7 mg implant | Ranibizumab 0.5 mg PRN+laser photocoagulation |
|---|---|---|---|---|---|---|
| Sham | – | |||||
| Ranibizumab 0.5 mg PRN | 10.6 (6.9 to 14.2)* | – | ||||
| Aflibercept 2q4 | 9.2 (1.7 to 16.1)* | −1.4 (−8.5 to 5.2) | – | |||
| Laser photocoagulation | −1.0 (−5.9 to 3.5) | −11.5 (−15.9 to −7.5)* | −10.2 (−15.5 to 4.6)* | – | ||
| Dexamethasone 0.7 mg implant | 2.5 (−1.1 to 6.3) | −8.0 (−11.9 to −4.0)* | −6.7 (−14.0 to 1.3) | 3.5 (−1.6 to 9.1) | – | |
| Ranibizumab 0.5 mg PRN+laser photocoagulation | 9.2 (3.4 to 14.5)* | −1.4 (−6.3 to 3.1) | −0.0 (−7.4 to 7.6) | 10.1 (5.1 to 15.3)* | 6.6 (0.4 to 12.3) | – |
*p<0.05.
2q4, 2 mg monthly; CrI, credible interval; PRN, pro re nata (as needed).